Form 4: Stoke Therapeutics Director Sells Shares

Sentiment:

Insider Transaction (Form 4)


Edward M. Kaye, a Director of Stoke Therapeutics, Inc., sold 12,567 shares of common stock on August 14, 2026.

Summary

  • Option exercise/conversion: acquired 26,250 Common Stock on August 14, 2026; holds 137,124 after (Direct).
  • Open-market sale: disposed of 11,930 Common Stock at $32.01 ($381,846) on August 18, 2026; holds 125,194 after (Direct).
  • Open-market sale: disposed of 637 Common Stock at $32.47 ($20,682) on August 18, 2026; holds 124,557 after (Direct).
  • Option exercise/conversion: disposed of 26,250 Performance Stock Units on August 14, 2026 (Direct).

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mildly negative signal: an insider sold $402,528 of stock on the open market.

Insider Transactions

Edward M. Kaye — Director

DateTransactionSecuritySharesPriceValueHeld After
2026-08-14Option exercise/conversionCommon Stock26,250——137,124
2026-08-18Open-market saleCommon Stock11,930$32$381.8K125,194
2026-08-18Open-market saleCommon Stock637$32$20.7K124,557
2026-08-14Option exercise/conversionPerformance Stock Units26,250——0

Key Dates

DateDescription
2026-08-14Option exercise/conversion (26,250 shares)
2026-08-18Open-market sale (11,930 shares)
2026-08-18Open-market sale (637 shares)
2026-08-14Option exercise/conversion (26,250 shares)

Keywords

insider transaction, Form 4, STOK, Stoke Therapeutics, Inc., bearish, Edward M. Kaye

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.